TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06336941

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasonographic scan with a 70 MHz probe
Study: NCT03594578

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Episodic future thinking
Description: Prospective thinking intervention

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Episodic recent thinking
Description: Sham episodic thinking
Study: NCT01502371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 25 mcg
Description: MF MDI 25 mcg (per inhalation), 2 puffs BID for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 50 mcg
Description: MF MDI 50 mcg (per inhalation), 2 puffs BID for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 100 mcg
Description: MF MDI 100 mcg (per inhalation), 2 puffs BID for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone Furoate (MF) Dry Powder Inhaler (DPI), 100 mcg
Description: MF DPI 100 mcg (per inhalation), 1 puff QD for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Metered Dose Inhaler (MDI)
Description: Placebo MDI, 2 puffs BID for 12 weeks
Study: NCT03205761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib tablet formulation at 600 mg total daily dose (given in two oral administrations of 300 mg every 12 hours approximately). Patients will continue to receive their treatment until objective disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent, whichever occurs first.
Study: NCT01502371

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Metered Dose Inhaler (MDI)
Description: Placebo MDI, 2 puffs BID for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Dry Powder Inhaler (DPI)
Description: Placebo DPI, 1 puff QD for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Dry Powder Inhaler (DPI)
Description: Placebo DPI, 1 puff QD for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Dry Powder Inhaler (DPI)
Description: Placebo DPI, 1 puff QD for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Dry Powder Inhaler (DPI)
Description: Placebo DPI, 1 puff QD for 12 weeks
Study: NCT03323814

Intervention type: DEVICE
Intervention: Slow-wave optimization
Description: employing sensory stimulation to enhance slow waves

Intervention type: DEVICE
Intervention: Slow-wave optimization
Description: employing sensory stimulation to enhance slow waves

Intervention type: DEVICE
Intervention: Slow-wave optimization
Description: employing sensory stimulation to enhance slow waves
Study: NCT04093583

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exodontia
Description: Atraumatic exodontia followed by simple suture

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Exodontia
Description: Atraumatic exodontia followed by simple suture

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alveolar ridge preservation with a PRP (PRGF-Endoret)
Description: Filling of the alveolus with PRGF clot and fibrin plug.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Preparation of PRGF using Endoret technology
Description: Preparation of PRGF using Endoret technology following manufacturer instructions
Study: NCT03433378

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tretinoin cream, 0.05%
Description: Tretinoin cream, 0.05%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RETIN-A® (tretinoin) cream, 0.05%
Description: RETIN-A® (tretinoin) cream, 0.05%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle of the test product
Description: Vehicle of the test product
Study: NCT02413502

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG
Description: BCG Vaccine USP attenuated live culture for percutaneous use (Merck) at 1-8 x 10\^8 CFUs.
Study: NCT03480737

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magstim Super Rapid2 stimulator, 10 Hz condition
Description: 10 Hz (2,000 pulses) at left DLPFC
Study: NCT01796197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mastectomy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Study: NCT04495504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Administration of a bolus dose of 10 ml of ropivacaine 7, 5 mg/mL in each catheter Continuous infusion of ropivacaine 2 mg/ml in a rate of 3 mL/h during the first 48 hours postoperatively.
Study: NCT03359486

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group problem management plus
Description: Low intensity group psychological intervention including stress management, behavioral activation, problem solving, and strengthening social support

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group problem management plus
Description: Low intensity group psychological intervention including stress management, behavioral activation, problem solving, and strengthening social support

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced treatment as usual
Description: Referral to primary care workers trained in mental health Gap Action Program Implementation Guide
Study: NCT03120208

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The IES-R, validated in French, with a discrimination threshold ≥ 30.
Description: The IES-R, validated in French, with a discrimination threshold ≥ 30.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The IES-R, validated in French, with a discrimination threshold ≥ 30.
Description: The IES-R, validated in French, with a discrimination threshold ≥ 30.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EPDS, MINI, STAI-A and B, IES-R and QEVA (experience)
Description: For the partners
Study: NCT04096573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LC51-0255
Description: LC51-0255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LC51-0255
Description: LC51-0255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LC51-0255
Description: LC51-0255

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LC51-0255
Description: LC51-0255

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01985477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Phase I All Patients - Induction: Lenalidomide starting dose 25 mg by mouth 1 time every day on Day 1-21.~Phase II Group A: Lenalidomide starting dose: Dose tolerated prior to enrollment.~Maintenance Therapy: Phase I and Phase II Group A: Maintenance therapy lenalidomide at dose level tolerated at completion of cycle 3 for 21/28 days.~Phase II Group B: Lenalidomide will be given as a single oral dose at the level patient was on at the time of progression on single agent lenalidomide prior to study enrollment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Phase I All Patients - Induction: Lenalidomide starting dose 25 mg by mouth 1 time every day on Day 1-21.~Phase II Group A: Lenalidomide starting dose: Dose tolerated prior to enrollment.~Maintenance Therapy: Phase I and Phase II Group A: Maintenance therapy lenalidomide at dose level tolerated at completion of cycle 3 for 21/28 days.~Phase II Group B: Lenalidomide will be given as a single oral dose at the level patient was on at the time of progression on single agent lenalidomide prior to study enrollment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Phase I All Patients - Induction: Dexamethasone starting dose 40 mg by mouth on Days 1,8,15,22.~Phase II Group A: Dexamethasone starting dose: Dose previously on when progressing prior to study entry.~Maintenance Therapy: Phase I and Phase II Group A: Dexamethasone at last tolerated dose on Days 1, 8, 15 and 22.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: All-Trans Retinoic Acid (ATRA)
Description: Phase I All Patients - Induction: ATRA starting dose 25 mg/m2 by mouth 2 times each day on Days 1-21.~Phase II Group A: ATRA starting dose: MTD from Phase I.~Maintenance Therapy: Phase I and Phase II Group A: ATRA at dose determined in Phase I for 14/28 days.~Phase II Group B: All-Trans Retinoic Acid (ATRA) starting dose: MTD from Phase I.~Maintenance Therapy Group B: ATRA at the dose determined in the Phase I portion of the trial for 14/28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: All-Trans Retinoic Acid (ATRA)
Description: Phase I All Patients - Induction: ATRA starting dose 25 mg/m2 by mouth 2 times each day on Days 1-21.~Phase II Group A: ATRA starting dose: MTD from Phase I.~Maintenance Therapy: Phase I and Phase II Group A: ATRA at dose determined in Phase I for 14/28 days.~Phase II Group B: All-Trans Retinoic Acid (ATRA) starting dose: MTD from Phase I.~Maintenance Therapy Group B: ATRA at the dose determined in the Phase I portion of the trial for 14/28 days.
Study: NCT00005028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bryostatin 1
Study: NCT03480737

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Magstim Super Rapid2 stimulator, Sham condition
Description: sham

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magstim Super Rapid2 stimulator, iTBS condition
Description: 50 Hz, iTBS (600 pulses) at left DLPFC
Study: NCT00005028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study: NCT00346996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin levemir / aspart
Description: for subcutaneous injection
Study: NCT02947204

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent oxygen monitoring
Description: Oxygen saturation and vital signs will be measured intermittently at a frequency of every 4 hours by the bedside nurse through the child's hospital stay until discharge. Vital signs will be completed every 4 hours.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous oxygen monitoring
Description: Oxygen saturation will be measured continuously through the child's hospital stay until discharge. Vital signs will be completed every 4 hours.
Study: NCT02558621

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AQrate Robotic Assistance System
Description: Robotic guidance during spinal fusion surgery
Study: NCT04448132

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IPV-Al
Description: adjuvanted reduced dose inactivated polio vaccine
Study: NCT02760212

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radial Shockwave Therapy
Description: 5 treatments in total scheduled weekly; RSWT to the painful areas will be undertaken with 500 shocks (1.5 bar, 15 Hz), then 1000 shocks (2 bar, 8 Hz), and finally 500 shocks (1.5 bar, 15 Hz) to the most painful spot within each of the 3 most painful regions as described by the participant.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Group 2 - Placebo Group
Description: 5 treatments in total scheduled weekly; placebo to the painful areas will be undertaken with 2000 shocks to the most painful spot within each of the 3 most painful regions as described by the participant.
Study: NCT00769067

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib
Description: Continuous oral dosing at 150 mg daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00299804
Description: Continuous oral dosing at 45mg daily
Study: NCT02340442

Intervention type: OTHER
Intervention: Obstetrical care parameters

Intervention type: OTHER
Intervention: Obstetrical care parameters

Intervention type: OTHER
Intervention: Obstetrical care parameters

Intervention type: OTHER
Intervention: DVA measurements

Intervention type: OTHER
Intervention: DVA measurements

Intervention type: OTHER
Intervention: DVA measurements

Intervention type: OTHER
Intervention: Fundus photographs

Intervention type: OTHER
Intervention: Fundus photographs

Intervention type: OTHER
Intervention: Fundus photographs
Study: NCT00775840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan
Description: Candesartan up to 32 mg, tablets, orally, once daily and ongoing angiotensin-converting enzyme inhibitor/beta-blocker therapy for up to 24 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Candesartan matching-placebo tablets, orally, once daily and ongoing angiotensin-converting enzyme inhibitor/beta-blocker therapy for up to 24 weeks.
Study: NCT03546972

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral, Psychological or Informational Intervention
Description: Take part in DDP

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral, Psychological or Informational Intervention
Description: Take part in DDP

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral, Psychological or Informational Intervention
Description: Take part in HT

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03487302

Intervention type: OTHER
Intervention: Brain MRI
Description: Acquisition of 3D T1-weighted, 3D FLAIR and GRE brain MRI scans

Intervention type: OTHER
Intervention: Brain MRI
Description: Acquisition of 3D T1-weighted, 3D FLAIR and GRE brain MRI scans

Intervention type: OTHER
Intervention: Neuropsychological test battery
Description: 1. Mini Mental State Examination (MMSE), Measso et al. (1993);~2. Frontal Assessment Battery (FAB), Appollonio et al. (2005);~3. Symbol Digit Test, Amodio et al. (2002);~4. Digit Cancellation Test, Della Sala et al. (1992);~5. Trial Making Test (TMT A-B), Giovagnoli et al. (1996);~6. Weigl's Sorting Test, Laicona et al. (2000) and Inzaghi (2010);~7. Digit Span, Orsini et al (1987);~8. Corsi block-tapping test, Orsini et al. (1987);~9. Babcock story recall test, Carlesimo et al. (2002);~10. Phonemic verbal fluency in MDB, Caltagirone and Carlesimo (2010);~11. Semantic verbal fluency, Novelli (1986);~12. Imitating gestures, De Renzi et al. (1980);~13. Coloured Progressive Matrices (CPM47), Measso et al. (1993).
Study: NCT00346996

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: human insulin /insulin isophane
Description: for subcutaneous injection
Study: NCT03329430

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foot orthoses
Description: Customized foot orthoses
Study: NCT01018563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MORAb-003
Description: Dose group to be determined by dose assigned in main study and patient's weight. Intravenous infusions are given every 3 weeks.
Study: NCT03228017

Intervention type: DRUG
Group type: OTHER
Intervention: Aspirin and/or Atorvastatin
Description: This follow-up will allow us to assess how aspirin and/or atorvastatin affect platelet and endothelial function and inflammation.
Study: NCT03259529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine hydrochloride
Description: 70 mg/m2 by intravenous (IV) infusion for up to 2 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine hydrochloride
Description: 70 mg/m2 by intravenous (IV) infusion for up to 2 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine hydrochloride
Description: 70 mg/m2 by intravenous (IV) infusion for up to 2 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine 500 mg
Description: 500 mg/m2 by intravenous (IV) infusion on day 1,8,15 for up to 2 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine 700 mg
Description: 700 mg/m2 by intravenous (IV) infusion on day 1,8,15 for up to 2 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1000 mg
Description: 1000 mg/m2 by intravenous (IV) infusion on day 1,8,15 for up to 2 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 1 mg/kg by intravenous (IV) infusion on day 1,15 for up to 2 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 1 mg/kg by intravenous (IV) infusion on day 1,15 for up to 2 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 1 mg/kg by intravenous (IV) infusion on day 1,15 for up to 2 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 by intravenous (IV) infusion on day 0 for up to 2 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 by intravenous (IV) infusion on day 0 for up to 2 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 by intravenous (IV) infusion on day 0 for up to 2 cycles
Study: NCT02584855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ixekizumab
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT03781765

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate
Description: stimulant medication

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atomoxetine
Description: non-stimulant medication
Study: NCT02258464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223 dichloride (Xofigo, BAY88-8223)
Description: Up to 6 cycles of radium-223 dichloride 50kBq/kg body (55 kBq/kg after implementation of National Institute of Standards and Technology \[NIST\] update)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (saline)
Description: Up to 6 cycles of saline injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Background hormonal therapy
Description: Prescribed by PI and was provided as long as patient can tolerate treatment. It must be prescribed as per local label in country participating.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Background hormonal therapy
Description: Prescribed by PI and was provided as long as patient can tolerate treatment. It must be prescribed as per local label in country participating.
Study: NCT04723160

Intervention type: DIAGNOSTIC_TEST
Intervention: Software assisted imaging diagnosis
Description: In the test group, diagnoses are given with the help of the software.
Study: NCT00932646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1744 (Olodaterol) Low Dose
Description: BI1744 Respimat low dose once daily and placebo Foradil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1744 (Olodaterol) Medium Dose
Description: BI1744 Respimat medium dose once daily and placebo Foradil

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Respimat once daily and placebo Foradil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Foradil
Description: 12 mcg twice daily and placebo Respimat
Study: NCT04170296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EN3835
Description: Collagenase Clostridium Histolyticum (CCH)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EN3835
Description: Collagenase Clostridium Histolyticum (CCH)
Study: NCT01435057

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: exercise training
Description: comparison of strength versus endurance training (two or three times a week, 60 minutes per training session) over 24 months

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: exercise training
Description: comparison of strength versus endurance training (two or three times a week, 60 minutes per training session) over 24 months
Study: NCT04555590

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: H-HOPE Intervention
Description: The H-HOPE intervention (Hospital to Home: Optimizing the Preterm Infant's Environment) to promote early infant development and parental engagement. H-HOPE includes ATVV, which provides Auditory (voice), Tactile (moderate touch massage), Visual (eye to eye), and Vestibular (rocking) stimulation with a parent-directed component which provides participatory guidance and social support to engage with their infants.
Study: NCT03508336

Intervention type: DIAGNOSTIC_TEST
Intervention: Coma Recovery Scale-Revised
Description: Patients with disorders of consciousness were assessed by Coma Recovery Scale-Revised (CRS-R). In addition, we selected four stimuli: 1) only a command (as recommended in CRS-R), which was open your mouth; 2) only a spoon without a command; 3) a spoon and a command, the command was there is a spoon and open your mouth; 4) a spoon with water and a command, the command was there is a spoon with water and open your mouth. In brief, we presented these stimuli orderly in front of the patient's mouth and presented any one of them over 4 trials at 15 second intervals.
Study: NCT04529603

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LungBrella marker implantation and VATS partial lobe resection
Description: The enrolled patients will receive a plain chest CT scan,then the data be loaded into JediVision software. The JediVision software can navigate the location of nodule and facilitate the implantation of LungBrella marker in the operating room after general anesthesia,then the patients will receive VATS partial lobe resection .
Study: NCT04243889

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NEOX Cord 1K
Description: Under general anesthesia and tocolysis, in-utero repair begins with a laparotomy that is followed by exteriorization of the uterus. The fetus is then positioned by external cephalic version. Uterine entry will be accessed using 3 cannulas, followed by heated-humidified carbon dioxide insufflation for visualization. Then, fetoscopically the placode will be examined and dissected. The lesion will be repaired using NEOX Cord 1K® (HUC) for closure of the first layer over the neural placode. Primary closure of the skin will then occur, or NEOX Cord 1K® (HUC) will be used for skin closure at the discretion of the neurosurgeon. Finally, the laparotomy site will be sutured in multiple layers.
Study: NCT04694482

Intervention type: OTHER
Intervention: Psychometric scale administration
Description: PTSD symptoms are assessed using a specific scale (IES-R) and compared between the two groups

Intervention type: OTHER
Intervention: Psychometric scale administration
Description: PTSD symptoms are assessed using a specific scale (IES-R) and compared between the two groups